Trial | NCT03112551  Report issue

Title

Safety and Efficacy of Twelve Hours Duration of MgSO4 in the Treatment of Eclampsia in Low Resource Setting in Sudan
Safety and Efficacy of Twelve Hours Duration of Magnesium Sulphate in the Treatment of Eclampsia in Low Resource Setting in Sudan

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    magnesium sulfate ...

  • Study Participants

    100
the investigators assume that magnesium sulphate for treating eclampsia can be safely reduced from 24 hours to shorter duration of therapeutic anticonvulsant effect for 12 hours. Short duration of drug exposure is suitable for low resource setting where there is little tools or busy staff for monitoring drug toxicity.
The idea of using 12 hours duration of magnesium sulphate for treating eclampsia may be effective and attractive, especially in settings with limited resources and where there is no availability of tools to monitor the serum level of magnesium sulphate. This is because the most common reported maternal adverse effects of magnesium sulphate are minor and may be confused with other symptom of eclampsia of even labor.The administration of Magnesium sulphate for 24 hours in the absence of monitoring of the serum magnesium sulphate might be life threatening in a resource- challenged situation , thus the current study is planned to be conducted to investigate the efficacy and safety of shorter duration (12 hours) of magnesium sulphate therapy in preventing development of convulsions in cases of eclampsia.
Study Started
Dec 01
2018
Anticipated
Primary Completion
Jun 30
2019
Anticipated
Study Completion
Jun 30
2019
Anticipated
Last Update
Mar 22
2018

Drug Adminstration of magnesium Sulphate for treatment of eclampsia

A total of 100 eclamptic patients are suspected to be approached alternately and subcategorized into two groups - one group will be treated with 24 hours maintenance dose of magnesium sulphate (Group-1; n=50), and the other with 12 hours maintenance dose of magnesium sulphate (Group-2; n=50).

group 1 Active Comparator

group one will be treated with 24 hours maintenance dose of magnesium sulphate

group 2 Experimental

group 2 will be treated with 12 hours maintenance dose of magnesium sulphate

Criteria 

Inclusion Criteria:

clinical diagnosis of eclampsia
must accept to participate in the study

Exclusion Criteria:

epilepsy
No Results Posted